MedTrace Logo

Cholecalciferol in Treating Patients With Myelodysplastic Syndrome

NCT00068276 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL

Last updated 2018-08-10

No results posted yet for this study

Summary

RATIONALE: Cholecalciferol (vitamin D) may improve quality of life by increasing blood counts, decreasing fatigue, and improving other symptoms of myelodysplastic syndrome.

PURPOSE: This phase II trial is studying how well cholecalciferol works in treating patients with myelodysplastic syndrome.

Conditions

Interventions

DIETARY_SUPPLEMENT

cholecalciferol

Sponsors & Collaborators

  • National Cancer Institute (NCI)

    collaborator NIH

  • Wake Forest University Health Sciences

    lead OTHER

Principal Investigators

  • Istvan Molnar, MD · Wake Forest University Health Sciences

  • Bayard L. Powell, MD · Wake Forest University Health Sciences

Study Design

Purpose
TREATMENT
Masking
NONE

Eligibility

Max Age
120 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2003-07-31
Primary Completion
2005-06-30
Completion
2006-09-30
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00068276 on ClinicalTrials.gov